Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
intravenous injection
|
| gptkbp:approvedBy |
gptkb:FDA
2012 |
| gptkbp:ATCCode |
L01XX45
|
| gptkbp:brand |
gptkb:carfilzomib
|
| gptkbp:CASNumber |
868540-17-4
|
| gptkbp:chemicalFormula |
C40H57N5O7
|
| gptkbp:contraindication |
hypersensitivity to carfilzomib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kyprolis
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Amgen
|
| gptkbp:mechanismOfAction |
protease inhibitor
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:anemia
nausea fatigue thrombocytopenia dyspnea |
| gptkbp:usedFor |
multiple myeloma
|
| gptkbp:bfsParent |
gptkb:carfilzomib
gptkb:Onyx_Pharmaceuticals |
| gptkbp:bfsLayer |
7
|